Overseas Version

VeriSee DR

Improving the quality of diabetes care

VeriSee DR is an AI-assisted diagnostic software for diabetic retinopathy (DR) that identifies high-risk DR patients. Its core AI model has been trained from images labeled by retina specialists, and the software has been validated in a pivotal clinical trial against a rigorous clinical reference standard. It leverages AI deep learning techniques to produce diagnosis results similar to that of professional ophthalmologists. It has a screening accuracy of 93% on referral recommendations.

The software helps healthcare professionals to analyze retinal images for signs of DR and immediately outputs recommendations on referral to ophthalmologists. Besides, it supports multiple retinal camera brands, such as Topcon, Canon, Crystalvue, Nikon, and MiiS and can be run on a device without network connection.

Request a demo
  • The first ophthalmic AI Software as a Medical Device (SaMD) approved by Taiwan FDA
  • Validated through rigorous clinical trial
  • Detection of four main DR lesions
  • Quick screening for high-risk DR cases
  • Supports integration with hospital information systems
References to additional clinical research data:
All-New Feature: Real-Time Lesion Detection

VeriSee DR detects the major lesions of DR and shows their corresponding locations. The referral recommendation results can be cross-referenced with the lesion detection results, which can reduce false positive and false negative results.

Four main DR lesions:
Microaneurysms
Hemorrhages
Soft Exudates
Hard Exudates

Diabetic Retinopathy Screening Faces Multiple Challenges

Shortage of ophthalmologists
The doctor-to-patient ratio is low across the world, resulting in overworked ophthalmologists and delayed diagnosis results.
Screenings at non-ophthalmology clinics
DR screenings are often conducted at diabetes clinics in certain markets, but diabetes specialists may not be trained in interpreting retinal images.
Delayed diagnosis reports
Without timely analysis, diabetes patients might miss the critical treatment period and face higher risks of vision loss and even blindness.
AI-powered Software to Optimize DR Screening Process

How It Works

Improving diabetic retinopathy diagnoses and disease tracking

Step 1
Step 1
Install the AI software on the computer connected to the fundus camera.
Step 2
Step 2
The software detects and analyzes new images in real-time, giving recommendations in 30 seconds with 93% accuracy. The AI software also provides the 4 major lesions with their corresponding locations.
Step 3
Step 3
The software produces a referral recommendation, assisting doctors in making diabetic retinopathy diagnosis efficiently.
Terms of Use End User Licensing Agreement

Why VeriSee DR

Efficient workflow and smooth integration

Completes image capturing, analysis, and diagnosis in one single session
Each time a new fundus image is detected by the software, the image is automatically uploaded to VeriSee DR for quality verification and diagnosis recommendation.
Handles a large number of cases efficiently with batch analysis mode
Up to 1000 fundus images can be uploaded to VeriSee DR at once. Analysis results are saved in CSV format to better integrate with the hospital's systems and for future research use.
Supports integration with the hospital's information system
Smooth integration with hospital information system (HIS), picture archiving and communication system (PACS), and the image capturing apparatus.
Enhances inter-departmental communication between endocrinologists and ophthalmologists and improves doctor-patient communication to increase patient awareness
Informative and user-friendly analysis reports that facilitate communication across multiple parties.

High performance and high accuracy

Result within seconds after image upload
sensitivity as validated in clinical trial
specificity as validated in clinical trial
accuracy as validated in clinical trial
1 The data analysis time period varies depending on the specifications of users’ device.
2 The above sensitivity and specificity performance is based on the results of a pivotal clinical trial approved by Taiwan FDA.

Recognized and Promoted by International Professional Communities

Journal of the Formosan Medical Association, 2020. Application of deep learning image assessment software VeriSeeTM for diabetic retinopathy screening.

The 12th Asia-Pacific Vitreo-Retina Society (APVRS) Congress,

– Seoul, South Korea, 2018

The 34th Asia-Pacific Academy of Ophthalmology (APAO) Congress,

– Bangkok, Thailand, 2019

Journal of the Formosan Medical Association, 2020. Application of deep learning image assessment software VeriSeeTM for diabetic retinopathy screening.

The 12th Asia-Pacific Vitreo-Retina Society (APVRS) Congress,

– Seoul, South Korea, 2018

The 34th Asia-Pacific Academy of Ophthalmology (APAO) Congress,

– Bangkok, Thailand, 2019

Explore more

Interested in Acer Medical’s Solutions?

Get started